Economic evaluation of precision medicine needs to start with the care pathway and include both diagnostics and treatments. This shifts the focus of the evaluation from single products to outcomes for patients, says Katarina Steen Carlsson and Oskar Frisell at the Swedish Institute for Health Economics when they presented the poster ”Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them?” at the Nordic Precision Cancer Medicine meeting i Oslo 17-19 september 2023.
